Benjamin Cheung, OD
Optometrist · Sparks, NVNPI 1316557622
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 121 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 22.0% — the pattern of someone who eats at a lot of different presentations.
Across 121 payments — averaging $32.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$868
- Alcon$822
- Biotissue Holdings Inc.$329
- Sun Pharmaceutical Industries Inc.$279
- Amgen$217
- Oyster Point Pharma, Inc.$170
- plus $1K from 15 others
What the payments were for
- Food & beverage$3,939100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 33 | $868 |
| Alcon | 22 | $822 |
| Biotissue Holdings Inc. | 14 | $329 |
| Sun Pharmaceutical Industries Inc. | 5 | $279 |
| Amgen(2 entities) | 6 | $217 |
| Oyster Point Pharma, Inc. | 4 | $170 |
| Tarsus Pharmaceuticals, Inc. | 3 | $149 |
| Sight Sciences, Inc. | 1 | $147 |
| LKC Technologies, Inc. | 1 | $132 |
| Apellis Pharmaceuticals, Inc. | 2 | $128 |
| Dompe US, Inc. | 5 | $125 |
| Johnson & Johnson Surgical Vision, Inc. | 5 | $114 |
| Novartis | 4 | $83 |
| Mallinckrodt Hospital Products Inc. | 4 | $82 |
| Aerie Pharmaceuticals, Inc. | 3 | $72 |
| Rxsight Inc | 3 | $66 |
| ANI Pharmaceuticals, Inc. | 2 | $52 |
| Harrow Eye, LLC | 1 | $35 |
| Merz Pharmaceuticals, LLC | 1 | $32 |
| Kala Pharmaceuticals, Inc. | 1 | $20 |
| Eyevance Pharmaceuticals LLC | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Hydrus Microstent$150
- TEARCARE SYSTEM$147
- ILUX$132
- TRYPTYR$125
- TYRVAYA$121
- TEPEZZA$114
- CEQUA$113
- XDEMVY$108
- VUITY$102
- Syfovre$100
How this compares
$3,939 in reported general payments places this provider in the 85th percentile of 494 optometrist providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XiidraLifitegrast | 112 | $177,335 |
| RestasisCyclosporine | 105 | $138,407 |
| Cyclosporine | 96 | $77,097 |
| XdemvyLotilaner | 24 | $44,382 |
| MieboPerfluorohexyloctane/Pf | 34 | $40,279 |
| CequaCyclosporine | 27 | $21,527 |
| TyrvayaVarenicline Tartrate | 11 | $17,316 |
| EysuvisLoteprednol Etabonate | 21 | $10,338 |
| VyzultaLatanoprostene Bunod | 11 | $5,055 |
| Epinastine Hcl | 29 | $3,040 |
| Loteprednol Etabonate | 11 | $1,678 |
| Fluorometholone | 19 | $1,545 |
| Prednisolone Acetate | 27 | $1,336 |
| Brimonidine Tartrate | 13 | $966 |
| Azelastine Hcl | 24 | $878 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis | $868 | $138,407105 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $149 | $44,38224 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $279 | $21,52727 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $170 | $17,31611 claims |
| Kala Pharmaceuticals, Inc.Eysuvis | $20 | $10,33821 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 494 optometrist providers in Nevada.
Other optometrist in Sparks
- Douglas DevriesSparks$1.3M
- Troy HumphreysSparks$52K
- Mackenzie MacintyreSparks$6K
- Timothy HunttingSparks$6K
- Warren WhitleySparks$4K
- Stella LauNorth Las Vegas$100K
- Eric BrookerLas Vegas$53K
- My VuongLas Vegas$47K
- Chen YoungLas Vegas$46K
- Harlan KopolowLas Vegas$36K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.